• DualityBio signed a global collaboration and license deal with Genentech to develop next-generation antibody-drug conjugates using its DUPAC payload platform.
• DualityBio will run discovery and early global clinical development; Genentech takes over development and commercialization after Phase 1a.
• Deal includes USD 45 million upfront payment, over USD 1 billion in potential milestones, and tiered royalties on net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608280008PR_NEWS_USPR_____CN35852) on August 28, 2026, and is solely responsible for the information contained therein.